Aardvark Therapeutics (AARD) Net Cash Flow (2024 - 2026)
Aardvark Therapeutics (AARD) posted Net Cash Flow of $15.4 million for Q1 2026, up 98.11% sequentially from $7.8 million in Q4 2025, and up 143.79% YoY from $6.3 million in Q1 2025.
Aardvark Therapeutics (AARD) Net Cash Flow (2024 - 2026) Analysis & Trends
Aardvark Therapeutics has reported Net Cash Flow for 3 years, with the latest figure at $15.4 million in Q1 2026.
- Quarterly Net Cash Flow rose 143.79% year-over-year to $15.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $35.9 million (up 89.47% YoY) and the FY2025 annual result came in at -$14.6 million, down 128.11% from the prior year.
- Net Cash Flow advanced to $15.4 million in Q1 2026 per AARD's latest filing, from $7.8 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $78.6 million in Q2 2024 and troughed at -$35.1 million in Q1 2025.
- A 3-year average of $5.9 million and a median of -$506000.0 in 2025 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 441.04% in 2025, down 1500.77% in 2025.
- Over 3 years, Net Cash Flow stood at -$20.6 million in 2024, then jumped by 137.63% to $7.8 million in 2025, then jumped by 98.11% to $15.4 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered $15.4 million, $7.8 million, and $13.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | 225.59 Mn |
| 10 | Aardvark Therapeutics | 140.91 Mn | 66.99 Mn | - | 11.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.41 Mn |
| Jun 30, 2026 | 11.41 Mn |
| Mar 31, 2026 | 15.39 Mn |
| Mar 31, 2026 | 15.39 Mn |
| Dec 31, 2025 | 7.77 Mn |
| Dec 31, 2025 | 7.77 Mn |
| Sep 30, 2025 | 13.29 Mn |
| Sep 30, 2025 | 13.29 Mn |
| Jun 30, 2025 | -506,000.00 |
| Jun 30, 2025 | -506,000.00 |
| Mar 31, 2025 | -35.14 Mn |
| Mar 31, 2025 | -35.14 Mn |
| Dec 31, 2024 | -20.64 Mn |
| Dec 31, 2024 | -20.64 Mn |
| Sep 30, 2024 | -3.90 Mn |
| Sep 30, 2024 | -3.90 Mn |
| Jun 30, 2024 | 78.63 Mn |
| Jun 30, 2024 | 78.63 Mn |
| Mar 31, 2024 | -2.20 Mn |
| Mar 31, 2024 | -2.20 Mn |